April 17, 2020

Thank you for your inquiry. Like all members of the medical community, Fresenius Kabi is closely monitoring the continuing threat of COVID-19. Our focus is employee safety and business continuity, and we’re taking steps globally and locally to help mitigate any potential disruption for our customers.

Fresenius Kabi has business-continuity plans in place. We maintain safety stock for many Fresenius Kabi pharmaceutical products and are increasing stock for products deemed essential in treating COVID-19 patients. Due to rising numbers of COVID-19 patients, all manufacturers of medicines used to treat ICU and ventilator patients are experiencing a significant surge in demand.

To help ensure the right products get where they are needed most, we are working closely with the U.S. Department of Health and Human Services, the U.S. Food and Drug Administration, the U.S. Federal Emergency Management Agency, and Health Canada, and we are prioritizing manufacturing based on their guidance. We are of course also in daily contact with pharmaceutical wholesalers, hospital purchasing groups and other customers.

Our manufacturing plants are fully operational and considered part of the essential country infrastructure responding to this crisis, and we are doing everything we can to produce what is needed under rapidly changing circumstances. Our people have been working around the clock to produce these medicines and we are grateful for their commitment to patients and health care professionals.

Currently we do not have any of our parenteral nutrition products on allocation, customers are receiving orders as placed. We have adequate supply of our lipid injectable emulsions, SMOFlipid® and Omegaven®, and based on demand do not anticipate any shortages. Kabiven® is in limited supply for some sizes, however we anticipate additional product to arrive by the end of April and will fulfill all orders and continue shipping without delay. If there are any fundamental changes to how we operate and serve customers due to COVID-19, we will advise you as soon as possible. And if you have questions about this, or anything else, please let us know.

###